Affiliation:
1. Cardiovascular Research Center , Tabriz University of Medical Sciences , Tabriz , Iran (Islamic Republic of)
2. Department of Anesthesiology , University at Buffalo , Buffalo NY, United States of America
Abstract
Abstract
Introduction. In-stent restenosis (ISR) remains a major limitation of percutaneous coronary intervention (PCI). A role for peripheral blood cells as major regulators of immune and inflammatory systems has been proposed. We aim to evaluate the relationship between eosinophil count and development of restenosis after drug-eluting stent (DES) implantation.
Methods. In this prospective study, all consecutive patients undergoing elective DES implantation for chronic stable angina (CSA) in a university-affiliated heart center within a 6-month period were enrolled and followed for another 6 months. Complete blood count with differentiation was performed 6 weeks after the index procedure. During the follow-up period, the cohort of patients who developed ISR was compared to the cohort of patients without ISR, descriptively and the total number of eosinophilic white cells was used to predict the occurrence of ISR.
Results. 153 men and 48 women with CSA underwent PCI with DES implantation, from which, 26 patients needed repeat coronary angiography for recurrent symptoms. There was an established ISR in 17 (8.5%) patients. The total number of eosinophils in their peripheral blood was 267 ± 132 cells/μL in patients with ISR, significantly higher than the number of eosinophils in those without ISR 174 ± 133 cells/μL (P-value < 0.010). Eosinophil count remained an independent predictor of ISR in multivariate analysis as the eosinophil count value over 242 cells/μL had sensitivity of 66.7% and specificity of 84.5% for the presence of ISR.
Conclusion. The total number of eosinophils, counted 6 weeks after DES implantation, prevails as the sole predictor of ISR occurrence in our study. This suggests an association between immune sensitivity reaction to DES material and development of ISR in patients after PCI.
Reference39 articles.
1. 1. KOLH P, WINDECKER S, ALFONSO F, COLLET J-P, CREMER J, FALK V et al. 2014 ESC/EACTS guidelines on myocardial revascularization. The task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European journal of cardio-thoracic surgery 2014, 46 (4):517-592.
2. 2. MACK MJ, BROWN PP, KUGELMASS AD, BATTAGLIA SL, TARKINGTON LG, SIMON AW et al. Current status and outcomes of coronary revascularization 1999 to 2002: 148,396 surgical and percutaneous procedures. The Annals of thoracic surgery 2004, 77 (3):761-766; discussion 766-768.
3. 3. MINTZ GS, HOFFMANN R, MEHRAN R, PICHARD AD, KENT KM, SATLER LF et al. In-stent restenosis: the Washington Hospital Center experience. The American journal of cardiology 1998, 81 (7a):7e-13e.
4. 4. MORRIS RE. Mechanisms of action of new immunosuppressive drugs. Therapeutic drug monitoring 1995, 17 (6):564-569.
5. 5. MARX SO, MARKS AR. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 2001, 104 (8):852-855.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献